Assessing Neurocrine Biosciences (NBIX) Valuation As Long Term Returns Outpace A Richer Earnings Multiple [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
Recent share performance and business snapshot Neurocrine Biosciences (NBIX) traded around $130.90 at the last close, with the stock showing mixed short term returns and a 50% total return over the past year, alongside annual revenue of US$2.86b and net income of US$478.6m. See our latest analysis for Neurocrine Biosciences. The recent 1 day share price return of 1.19% decline and 7 day return of 0.64% decline sit against a much stronger 1 year total shareholder return of 49.53%, suggesting that longer term momentum has been building even as shorter term sentiment has softened slightly. If you are looking beyond Neurocrine Biosciences for more ideas in health related technology, this is a good moment to review the 37 healthcare AI stocks With Neurocrine Biosciences trading at US$130.90 and referenced estimates suggesting higher intrinsic and target values, investors may question whether the current price still offers potential upside or if the market is already factoring in
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine to acquire Soleno in $2.9bn transaction [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences (NBIX) had its price target raised by Citigroup Inc. from $204.00 to $242.00. They now have a "buy" rating on the stock.MarketBeat
- Neurocrine Biosciences (NBIX) had its price target raised by Canaccord Genuity Group Inc. from $164.00 to $200.00. They now have a "buy" rating on the stock.MarketBeat
- Neurocrine Biosciences (NBIX) had its price target raised by Wedbush from $151.00 to $166.00. They now have an "outperform" rating on the stock.MarketBeat
- Neurocrine Biosciences (NBIX) had its price target raised by HC Wainwright from $192.00 to $215.00. They now have a "buy" rating on the stock.MarketBeat
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 4/6/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- 3/17/26 - Form 3
- NBIX's page on the SEC website